4-(4-Chlorophenyl)piperidine-4-carbonitrile, 95.0%, 250mg

Ethyl 5-bromoindole-2-carboxylate., 98.0%, 500g

3-Bromo-5-(prop-1-en-2-yl)pyridine, 95.0%, 1g

Pentatriacontan-18-one, 98%, 5g

(2-aminocyclohexyl)methanol hydrochloride, 95.0%, 500mg

Ethyl 4-chloro-2-methylthiopyrimidine-5-carboxylate, 97.0%, 500g

Ethyl 2-Amino-1,3-oxazole-5-carboxylate, 97.0%, 1g

(R)-2-(2,4-Dichlorophenoxy)propanoic acid, 95%, 1g

Anti-Human IgG Fc C-terminus Monoclonal Antibody1vial

Plan PLPH 20x/0.40 phase contrast objective

(T-4)-[[2,2'-[(1S,2S)-1,2-Cyclohexanediylbis[(nitrilo-κN)methylidyne]]bis[4,6-bis(1,1-dimethylethyl)phenolato-κO]](2-)]zinc, 95%, 10g

(3-((4-Methylpiperidin-1-yl)methyl)phenyl)boronic acid, 98+%, 1g

N-(Cyclohexylmethyl)cyclopropanamine, 95.0%, 1g